Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Imagine trying to design a key for a lock that is constantly changing its shape. That is the exact challenge we face in modern drug discovery when dealing with intrinsically disordered proteins.

This week, astronomers reported that one of the biggest observed stars in the universe could soon explode. A study compared ...

Those that solve artificially simplified problems where quantum advantage is meaningless. Those that provide no genuine quantum advantage when all costs are properly accounted for. This critique is ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Abstract: RNA's diverse biological functions, including gene regulation, enzymatic catalysis, signal transduction, and even therapeutic activity, ultimately depend on its three-dimensional (3D) ...